BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29992404)

  • 1. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.
    Cardenas-Goicoechea J; Wang Y; McGorray S; Saleem MD; Carbajal Mamani SL; Pomputius AF; Markham MJ; Castagno JC
    J Robot Surg; 2019 Feb; 13(1):23-33. PubMed ID: 29992404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
    Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
    Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
    Jorgensen K; Melamed A; Wu CF; Nitecki R; Pareja R; Fagotti A; Schorge JO; Ramirez PT; Rauh-Hain JA
    Gynecol Oncol; 2023 May; 172():130-137. PubMed ID: 36977622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer.
    Conte C; Marchetti C; Loverro M; Giudice MT; Rosati A; Gallotta V; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2023 Feb; 33(2):137-144. PubMed ID: 36639195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE).
    Nitecki R; Rauh-Hain JA; Melamed A; Scambia G; Pareja R; Coleman RL; Ramirez PT; Fagotti A
    Int J Gynecol Cancer; 2020 Sep; 30(9):1450-1454. PubMed ID: 32690591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
    Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
    J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis.
    Knisely A; Gamble CR; St Clair CM; Hou JY; Khoury-Collado F; Gockley AA; Wright JD; Melamed A
    J Minim Invasive Gynecol; 2021 Mar; 28(3):537-543. PubMed ID: 33202311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study).
    Pomel C; Akladios C; Lambaudie E; Rouzier R; Ferron G; Lecuru F; Classe JM; Fourchotte V; Paillocher N; Wattiez A; Montoriol PF; Thivat E; Beguinot M; Canis M
    Int J Gynecol Cancer; 2021 Dec; 31(12):1572-1578. PubMed ID: 34670829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epithelial ovarian cancers and minimally invasive cytoreductive surgery after neoadjuvant chemotherapy: A systematic review].
    Achen G; Koual M; Bentivegna E; Fournier L; Nguyen Xuan HT; Delanoy N; Bats AS; Azaïs H
    Gynecol Obstet Fertil Senol; 2021 Oct; 49(10):736-743. PubMed ID: 33636412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
    Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
    Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of the current debate between using minimally invasive surgery versus laparotomy for interval cytoreductive surgery in epithelial ovarian cancer.
    Finch L; Chi DS
    J Gynecol Oncol; 2023 Sep; 34(5):e84. PubMed ID: 37545363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy.
    Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G
    Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally invasive interval cytoreductive surgery for advanced ovarian cancer.
    Melamed A; Eisenhauer EL
    J Surg Oncol; 2024 Jan; 129(1):126-127. PubMed ID: 38073159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer.
    Menderes G; Black JD; Azodi M
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):899-901. PubMed ID: 27477495
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-Institution Propensity-Matched Study to Evaluate the Psychological Effect of Minimally Invasive Interval Debulking Surgery Versus Standard Laparotomic Treatment: From Body to Mind and Back.
    Gueli Alletti S; Vizzielli G; Lafuenti L; Costantini B; Fagotti A; Fedele C; Cianci S; Perrone E; Gallotta V; Rossitto C; Scambia G
    J Minim Invasive Gynecol; 2018; 25(5):816-822. PubMed ID: 29269126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer.
    Conte C; Rosati A; Marchetti C; Iacobelli V; Quagliozzi L; Gallucci V; Gueli Alletti S; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2022 Apr; 32(4):532-539. PubMed ID: 35022309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.